Prof Garbe speaks with ecancer at EADO 2017 about targeted therapies for advanced and metastatic melanoma.

He describes the tremendous improvements in survival for metastatic disease treated with targeted therapy, from ~5% to ~40%, and considers how tumour evolution may expose ways to subvert treatment resistance with new druggable targets.

By combining multiple targets in combination or in sequence, Prof Garbe hopes for even greater survival improvements.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.